PPD in the News

Brent Denton, John Bak and Jonathon Salsbury discuss how light obscuration testing is the preferred method of sub-visible particle quantification, but is not suitable for every preparation.

PPD is extending its digital clinical trial offering to support its biopharma clients' R&D as life science companies continue to find workarounds on trial delays.

Accelerated Enrollment Solutions has introduced a new program to help biopharmaceutical companies maintain business continuity during the global COVID-19 pandemic.

Accelerated Enrollment Solutions and Science 37 are collaborating to recruit and enroll clinical trial participants who live beyond the geographic location of traditional research sites.

Mel Formica, global head, value and development consulting, Evidera, discusses the challenges regulators face as they seek to understand the acceptability of cutting-edge real-world data.

Kristopher Garibay, Eric Olson and Jonathon Salsbury of PPD® Laboratories GMP Lab discuss how the use of particle size distribution profiles by laser diffraction is a common analytical technique utilized across multiple industries.

Can investing in early formulation studies drive a new therapy successfully across the commercialization finish line?

Contract service organizations can offer biopharma companies early insight into dangers that may hinder a drug’s later development.

Patients are sharing their stories in an effort to educate other stakeholders, and the pharma industry is using that knowledge sharing to improve on messaging and patient interaction.